Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONYX: Long-Term Safety and Efficacy of Apitegromab in SMA
NCT05626855Phase 3Active, not recruiting
- Sponsor
- Scholar Rock
- Start
- Apr 2023
- Primary completion
- Nov 2026
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 3, open-label, single-arm trial of apitegromab in spinal muscular atrophy (SMA), sponsored by Scholar Rock. Primary endpoint: Long-term safety and tolerability up to 6 years. Started Apr 2023; status: active, not recruiting.
02
Drugs
apitegromab
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on NCT05626855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05626855.